SCHEMBL139043

SCHEMBL139043

COc1cc(OC)cc(C(=O)C(O)c2ccccc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
CES2 O00748 1/20 0.59
CES1 P23141 1/20 0.59
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
GPR139 Q6DWJ6 1/20 0.49
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TACR1 P25103 2/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL2779583 0.98 LMNA (0.58) LMNACES2CES1MEN1KMT2A
Carbamic Acid SCHEMBL1695355 0.95 LMNA (0.54) LMNACES2CES1MEN1KMT2A
SCHEMBL6203480 0.87 CES2 (0.61) LMNACES2CES1MEN1KMT2A
SCHEMBL139044 0.87 CES2 (0.59) LMNACES2CES1MEN1KMT2A
SCHEMBL14181968 0.86 CES2 (0.48) CES2CES1MEN1KMT2AKDM4E
Bicarbonate SCHEMBL291493 0.85 CES2 (0.58) LMNACES2CES1MEN1KMT2A
SCHEMBL29262742 0.85 LMNA (0.67) LMNACES2CES1MEN1KMT2A
Benzoin SCHEMBL15326953 0.85 LMNA (0.72) LMNACES2CES1MEN1KMT2A
SCHEMBL812736 0.85 LMNA (0.67) LMNACES2CES1MEN1KMT2A
Acetic Acid SCHEMBL3368380 0.84 CES2 (0.56) LMNACES2CES1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300067-B1 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIV OF BELFAST (GB) 2017-10-25 EP claimed
US-9714560-B2 Protected scale inhibitors and methods relating thereto HALLIBURTON ENERGY SERVICES, INC. (US) 2017-07-25 US claimed
US-20110165114-A1 DRUG DELIVERY COMPOSITION QUEEN'S UNIVERSITY OF BELFAST, THE (GB) 2011-07-07 US claimed
EP-2300067-A2 DRUG DELIVERY COMPOSITION The Queen's University of Belfast (GB) 2011-03-30 EP claimed
WO-2009147372-A2 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2009-12-10 WO claimed
EP-1401851-B8 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS FEBIT HOLDING GMBH (DE) 2008-09-10 EP claimed
EP-1401851-A1 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS Febit AG (DE) 2004-03-31 EP claimed
WO-2003004510-A1 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS FEBIT AG (DE) 2003-01-16 WO claimed
WO-2026090073-A1 POLYMERIC PARTICLES FOR PROXIMITY-BASED CELLULAR DNA-ENCODED LIBRARY SCREENING AND METHODS OF USE GENENTECH, INC. (US) 2026-04-30 WO disclosed
EP-4695264-A1 LIQUID-PHASE PROCESS FOR PREPARING OLIGONUCLEOTIDES Exactmer Limited (GB) 2026-02-18 EP disclosed
US-20250344929-A1 Fibrous Structures Comprising Particles and Methods for Making Same PROCTER & GAMBLE (US) 2025-11-13 US disclosed
EP-4197598-B1 ACTIVE AGENT-CONTAINING ARTICLES THAT EXHIBIT CONSUMER ACCEPTABLE ARTICLE IN-USE PROPERTIES PROCTER & GAMBLE (US) 2025-10-22 EP disclosed
US-12440083-B2 Fibrous structures comprising particles and methods for making same THE PROCTER & GAMBLE COMPANY (US) 2025-10-14 US disclosed
EP-3915643-B1 ACTIVE AGENT-CONTAINING ARTICLES THAT EXHIBIT CONSUMER ACCEPTABLE ARTICLE IN-USE PROPERTIES PROCTER & GAMBLE (US) 2025-08-20 EP disclosed
US-4599273-A PROTECTIVE COATINGS, PRESSURE SENSITIVE ADHESIVES MINNESOTA MINING AND MANUFACTURING CO. (US) 1986-07-08 US disclosed
EP-0046083-B1 PHOTOLABILE BLOCKED SURFACTANTS AND COMPOSITIONS CONTAINING THE SAME MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1985-10-16 EP disclosed
EP-0123159-A2 Positive-working photosensitive benzoin esters E.I. DU PONT DE NEMOURS AND COMPANY (US) 1984-10-31 EP disclosed
US-4478967-A Photolabile blocked surfactants and compositions containing the same MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1984-10-23 US disclosed
US-4469774-A RELIEF PRINTING PLATES, PHOTORESISTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-09-04 US disclosed
EP-0046083-A2 Photolabile blocked surfactants and compositions containing the same MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1982-02-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165114-A1 DRUG DELIVERY COMPOSITION ECPAS, ABCB11, ABCB1 LMNA 135/4885CES2 427/4885CES1 714/4885
US-12440083-B2 Fibrous structures comprising particles and methods for making same FGB, CD68, SDCBP LMNA 166/4885CES2 2307/4885CES1 2200/4885
US-20250344929-A1 Fibrous Structures Comprising Particles and Methods for Making Same FGB, CD68, SDCBP LMNA 166/4885CES2 2307/4885CES1 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.